ANNX - Annexon Inc.

-

$undefined

N/A

(N/A)

Annexon Inc. NasdaqGS:ANNX Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Location: 1400 Sierra Point Parkway, Brisbane, CA, 94005, United States | Website: https://www.annexonbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-14.86M

Cash

263.7M

Avg Qtr Burn

-34.95M

Short % of Float

12.09%

Insider Ownership

0.57%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ANX005 (IV) Details
Guillian-Barre syndrome, Autoimmune disease

BLA

Submission

ANX007 (IVT) Details
Geographic atrophy

Phase 3

Data readout

ANX005 (IV) Details
Huntington's disease, Brain disease

Phase 3

Initiation

ANX005 (IV) Details
Amyotrophic lateral sclerosis, Neurodegenerative disease

Phase 2a

Update

ANX009 Details
Lupus nephritis

Phase 1b

Update

ANX105 Details
Autoimmune disease, Neurodegenerative disease

Phase 1

Data readout

ANX1502 Details
Cold agglutinin disease

Phase 1a

Data readout

ANX005 (IV) Details
Warm autoimmune hemolytic anemia, Autoimmune disease

Failed

Discontinued